Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TINCRBEL study
2024-519078-38-00Phase 4Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rivaroxaban in venous thromboembolism (VTE), Atrial fibrillation (AFib) and stroke, sponsored by Amsterdam University Medical Center. Primary endpoints: Clinical efficacy outcomes at one year and Clinical safety outcomes at one year. Planned start Nov 2024; status: authorised.
02
Drugs
rivaroxaban
03
Conditions
venous thromboembolism (VTE)Atrial fibrillation (AFib)stroke
Beyond the preview
Go deeper on 2024-519078-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519078-38-00.